Another prognostic biomarker, GAS6-AS1, is a potential target for therapeutic approaches in hepatocellular carcinoma (HCC), where knock-down of GAS6-AS1 decreased tumor growth in vivo (Ai et al., 2020). This evidence concerns the gene GAS6 and hepatocellular carcinoma.